Fibrin-selective thrombolytic therapy for acute myocardial infarction

Circulation

Volumn 93, Issue 5, 1996, Pages 857-865

  Collen, D ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Bench to Beside fibrin; myocardial infarction; thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; FIBRIN; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; STAPHYLOKINASE; STREPTOKINASE; UROKINASE;

ACUTE HEART INFARCTION; ANIMAL MODEL; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HEART INFARCTION SIZE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0029915080     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.5.857     Document Type: Review

References (90)

1. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J. 1985;53:363-373.
2. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303:897-902.
3. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood. 1991;78:3114-3124.
4. Fletcher AP, Alkjaersig N, Smyrniotis FE, Sherry S. Treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Trans Assoc Am Physicians. 1958; 71:287-296.
5. European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction. Streptokinase in acute myocardial infarction. N Engl J Med. 1979;301:797-802.
6. Astrup T. Fibrinolysis: past and present, a reflection of fifty years. Semin Thromb Hemost. 1991;17:161-174.
7. Sherry S. The origin of thrombolytic therapy. J Am Coll Cardiol. 1989;14:1085-1092.
8. Rentrop KP, Blanke H, Karsch KR, Wiegand V, Kostering K, Oster H, Leitz K. Acute myocardial infarction: intracoronary application of nitroglycerin and streptokinase. Clin Cardiol. 1979;2:354-363.
9. Chazov EL, Matveeva LS, Mazaev AV, Sargin KE, Sadovskaia GV, Ruda MI. Intracoronary administration of fibrinolysis in acute myocardial infarction. Ter Arkh. 1976;48:8-19.
10. Collen D, Verstraete M. Systemic thrombolytic therapy of acute myocardial infarction? Circulation. 1983;68:462-465.
11. Schröder R, Biamino G, von Leitner ER, Linderer T, Bruggemann T, Heitz J, Vohringer HF, Wegscheider K. Intravenous short-term infusion of streptokinase in acute myocardial infarction. Circulation. 1983;67:536-548.
12. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-402.
13. Collen D. On the regulation and control of fibrinolysis: Edward Kowalski Memorial Lecture. Thromb Haemost. 1980;43:77-89.
14. Collen D. Regulation of fibrinolysis: plasminogen activator as a thrombolytic agent. In: Nossel HL, Vogel HJ, eds. Pathobiology of the Endothelial Cell. New York, NY: Academic Press; 1982:183-189.
15. The TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial: phase I findings. N Engl J Med. 1985;312:932-936.
16. Verstraete M, Bernard R, Bory M, Brower RW, Collen D, de Bono DP, Erbel R, Huhmann W, Lennane RJ, Lubsen J, Mathey D, Meyer J, Michels HR, Rutsch W, Schartl M, Schmidt W, Uebis R, von Essen R. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction: report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet. 1985;1:842-847.
17. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet. 1990;336:71-75.
18. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 1992;339:753-770.
19. Collen D. Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator? Ann Intern Med. 1990;112: 529-538.
20. Sobel BE, Collen D. Strokes, statistics and sophistry in trials of thrombolysis for acute myocardial infarction. Am J Cardiol. 1993; 71:424-427.
21. Sherry S, Marder VJ. Creation of the recombinant tissue plasminogen activator (rt-PA) image and its influence on practice habits. J Am Coll Cardiol. 1991;18:1579-1582.
22. Collins R, Peto R, Parish S, Sleight P, After ISIS-3. Lancet. 1992; 339:1226-1227. Reply.
23. Lenfant C. The rt-PA versus streptokinase controversy, I. J Am Coll Cardiol. 1992;19:1116.
24. Braunwald E, Knatterud G, Passamani E. The rt-PA versus streptokinase controversy, II. J Am Coll Cardiol. 1992;19:1116-1119.
25. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
26. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
27. Braunwald E. The open-artery theory is alive and well - again. N Engl J Med. 1993;329:1650-1652.
28. Collen D. Towards improved thrombolytic therapy. Lancet. 1993; 342:34-36.
29. Lijnen HR, Collen D. Experimental studies in thrombolysis and fibrinolysis. Curr Opin Cardiol. 1993;8:613-620.
30. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet. 1995;346: 329-336.
31. Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, Lai J, Pena L, Pater C, Ogez J, Etcheverry T, Botstein D, Bennett WF. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A. 1994;91:3670-3674.
32. Collen D, Stassen JM, Yasuda T, Refino CJ, Paoni N, Keyt B, Roskams T, Guerrero JL, Lijnen HR, Gold HK, Bennett WF. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost. 1994;72:98-104.
33. Witt W, Maass B, Baldus B, Hildebrand M, Donner P, Schleuning WD. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs: fast and persistent recanalization by intravenous bolus administration. Circulation. 1994;90:421-426.
34. Haber E, Quertermous T, Matsueda GR, Runge MS. Innovative approaches to plasminogen activator therapy. Science. 1989;243: 51-56.
35. Anderson HV, Willerson JT. Thrombolysis in acute myocardial infarction. N Engl J Med. 1993;329:703-709.
36. Collen D, Lijnen HR. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential? Blood. 1994;84:680-686.
37. Vanderschueren S, Barrios L, Kerdsinchai P, Van den Heuvel P, Hermans L, Vrolix M, De Man F, Benit E, Muyldermans L, Collen D, Van de Werf F. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation. 1995;92:2044-2049.
38. Collen D, Zhao ZA, Holvoet P, Marijnen P. Primary structure and gene structure of staphylokinase. Fibrinolysis. 1992;6:226-231.
39. Collen D, Bernaerts R, Declerck PJ, De Cock F, Demarsin E, Jenné S, Laroche Y, Lijnen HR, Silence K, Verstreken M. Recombinant staphylokinase variants with altered immunoreactivity, I: construction and characterization. Circulation. In press.
40. Collen D, Moreau H, Stockx L, Vanderschueren S. Recombinant staphylokinase variants with altered immunoreactivity, II: thrombolytic properties and antibody induction. Circulation. In press.
41. Collen D, Tytgat G, Claeys H, Verstraete M, Wallén P. Metabolism of plasminogen in healthy subjects: effect of tranexamic acid. J Clin Invest. 1972;51:1310-1318.
42. Collen D, Vermylen J. Metabolism of iodine-labeled plasminogen during streptokinase and reptilase therapy in man. Thromb Res. 1973;2:239-250.
43. Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem. 1976;69: 209-216.
44. Müllertz S, Clemmensen I. The primary inhibitor of plasmin in human plasma. Biochem J. 1976;159:545-553.
45. Moroi M, Aoki N. Isolation and characterization of alpha 2-plasmin inhibitor from human plasma: a novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem. 1976;251: 5956-5965.
46. Wiman B, Collen D. Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma. Eur J Biochem. 1977;78:19-26.
47. Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem. 1978;84:573-578.
48. Lijnen HR, Collen D. Natural inhibitors of fibrinolysis. In: Bloom AL, Thomas DP, eds. Thrombosis and Haemostasis. 2nd ed. Edinburgh, UK: Churchill Livingstone; 1987:255-266.
49. Wiman B, Collen D. Molecular mechanism of physiological fibrinolysis. Nature. 1978;272:549-550.
50. Reich E, Rifkin DB, Shaw E, eds. Proteases and Biological Control. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1975.
51. Collen D, Billiau A, Edy J, De Somer P. Identification of the human plasma protein which inhibits fibrinolysis associated with malignant cells. Biochim Biophys Acta. 1977;499:194-201.
52. Wallén P. Activation of plasminogen with urokinase and tissue activator. In: Paoletti R, Sherry S, eds. Thrombosis and Urokinase. London, UK: Academic Press; 1977:91-102.
53. Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem. 1981;256:7035-7041.
54. Collen D, Rijken DC, Van Damme J, Billiau A. Purification of human tissue-type plasminogen activator in centigram quantities from human melanoma cell culture fluid and its conditioning for use in vivo. Thromb Haemost. 1982;48:294-296.
55. Matsuo O, Rijken DC, Collen D. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Thromb Haemost. 1981; 45:225-229.
56. Matsuo O, Rijken DC, Collen D. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature. 1981;291:590-591.
57. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator: role of fibrin. J Biol Chem. 1982;257:2912-2919.
58. Collen D, Stassen JM, Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis: effect of molecular form and dose of activator, age of the thrombus, and route of administration. J Clin Invest. 1983;71:368-376.
59. Weimar W, Stibbe J, van Seyen AJ, Billiau A, De Somer P, Collen D. Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator. Lancet. 1981;2: 1018-1020.
60. Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature. 1983;301: 214-221.
61. Collen D, Stassen JM, Marafino BJ Jr, Builder S, De Cock F, Ogez J, Tajiri D, Pennica D, Bennett WF, Salwa J, Hoyng CF. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. J Pharmacol Exp Ther. 1984;231:146-152.
62. Van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KA, de Geest H, Verstraete M, Collen D, Sobel BE. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med. 1984;310:609-613.
63. Bergmann SR, Fox KA, Ter-Pogossian MM, Sobel BE, Collen D. Clot-selective coronary thrombolysis with tissue-type plasminogen activator. Science. 1983;220:1181-1183.
64. Van de Werf F, Bergmann SR, Fox KA, de Geest H, Hoyng CF, Sobel BE, Collen D. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. Circulation. 1984;69:605-610.
65. Gold HK, Fallon JT, Yasuda T, Leinbach RC, Khaw BA, Newell JB, Guerrero JL, Vislosky FM, Hoyng CF, Grossbard E, Collen D. Coronary thrombolysis with recombinant human tissue-type plasminogen activator. Circulation. 1984;70:700-707.
66. Collen D, Topol EJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML, Sobel BE, Leinbach RC, Brinker JA, Ludbrook PA, Yasuda I, Bulkley BH, Robison AK, Hutter AM, Bell WR, Spadaro JJ, Khaw BA, Grossbard EB. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation. 1984;70:1012-1017.
67. Becker RC, ed. The Modem Era of Coronary Thrombolysis. Boston, Mass: Kluwer Academic Publishers; 1994.
68. Sako T, Sawaki S, Sakurai T, Ho S, Yoshizawa Y, Kondo I. Cloning and expression of the staphylokinase gene of Staphylococcus aureus in Escherichia coli. Mol Gen Genet. 1983;190:271-277.
69. Behnke D, Gerlach D. Cloning and expression in Escherichia coli, Bacillus subtilis, and Streptococcus sanguis of a gene for staphylokinase: a bacterial plasminogen activator. Mol Gen Genet. 1987; 210:528-534.
70. Matsuo O, Okada K, Fukao H, Tomioka Y, Ueshima S, Watanuki M, Sakai M. Thrombolytic properties of staphylokinase. Blood. 1990;76:925-929.
71. Lijnen HR, Van Hoef B, De Cock F, Okada K, Ueshima S, Matsuo O, Collen D. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J Biol Chem. 1991;266:11826-11832.
72. 2-antiplasmin and fibrin. Biochim Biophys Acta. 1992;1118:144-148.
73. Lijnen HR, De Cock F, Matsuo O, Collen D. Comparative fibrinolytic and fibrinogenolytic properties of staphylokinase and streptokinase in plasma of different species in vitro. Fibrinolysis. 1992;6:33-37.
74. Lijnen HR, Stassen JM, Vanlinthout I, Fukao H, Okada K, Matsuo O, Collen D. Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis. Thromb Haemost. 1991;66:468-473.
75. Collen D, Silence K, Demarsin E, De Mol M, Lijnen HR. Isolation and characterization of natural and recombinant staphylokinase. Fibrinolysis. 1992;6:203-213.
76. Lijnen HR, Van Hoef B, Vandenbossche L, Collen D. Biochemical properties of natural and recombinant staphylokinase. Fibrinolysis. 1992;6:214-225.
77. 2-antiplasmin. J Biol Chem. 1993;268:9811-9816.
78. 2-antiplasmin and fibrin of the activation of plasminogen with recombinant staphylokinase in plasma. Blood. 1993;82:1175-1183.
79. Collen D, De Cock F, Vanlinthout I, Declerck PJ, Lijnen HR, Stassen JM. Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase. Fibrinolysis. 1992;6: 232-242.
80. Collen D, De Cock F, Stassen JM. Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons. Circulation. 1993;87:996-1006.
81. Collen D, De Mol M, Demarsin E, De Cock F, Stassen JM. Isolation and conditioning of recombinant staphylokinase for use in man. Fibrinolysis. 1993;7:242-247.
82. Collen D, Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation. 1993;87:1850-1853.
83. Schlott B, Hartmann M, Gührs KH, Birch-Hirschfeld E, Pohl HP, Vanderschueren S, Van de Werf F, Michoel A, Collen D, Behnke D. High yield production and purification of recombinant staphylokinase for thrombolytic therapy. Biotechnology. 1994;12:185-189.
84. Collen D, Schlott B, Engelborghs Y, Van Hoef B, Hartmann M, Lijnen HR, Behnke D. On the mechanism of the activation of human plasminogen by recombinant staphylokinase. J Biol Chem. 1993;268:8284-8289.
85. Collen D, Van Hoef B, Schlott B, Hartmann M, Gührs KH, Lijnen HR. Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase. Eur J Biochem. 1993;216:307-314.
86. Schlott B, Hartmann M, Gührs KH, Birch-Hirschfeld E, Gase A, Vettermann S, Collen D, Lijnen HR. Functional properties of recombinant staphylokinase variants obtained by site-specific mutagenesis of methionine-26. Biochim Biophys Acta. 1994;1204: 235-242.
87. Lijnen HR, De Cock F, Van Hoef B, Schlott B, Collen D. Characterization of the interaction between plasminogen and staphylokinase. Eur J Biochem. 1994;224:143-149.
88. Vanderschueren S, Stockx L, Wilms G, Lacroix H, Verhaeghe R, Vermylen J, Collen D. Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase. Circulation. 1995;92: 2050-2057.
89. Declerck PJ, Vanderschueren S, Billiet J, Moreau H, Collen D. Prevalence and induction of circulating antibodies against recombinant staphylokinase. Thromb Haemost. 1994;71:129-133.
90. Vanderschueren SMF, Stassen JM, Collen D. On the immunogenicity of recombinant staphylokinase in patients and in animal models. Thromb Haemost. 1994;72:297-301.